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ABSTRACT 
The basic aim of  of this study is the formulation, evaluation and optimization of immediate 
release amlodipine tablet IP 5mg film coated tablets by wet granulation method. Amlodipine is 
used in the treatment of mild to moderate hypertension, chronic stable angina pectoris or 
vasopastic angina (prinz metals or variant).Totally 9 preparations are prepared with 
Amlodipine.Sodium starch glycolate,Starch used as disintegrants,Magnesium stearate(lubricant). 
The amlodipine granules prepared separately in a rapid mixer granulator.Pre compression 
parameters like bulk density, true density, angle of repose, Compressibility index, Hausner’s 
ratio indicate all the formulations are showing good flow properties. Granules are compressed to 
produce tablets are evaluated for post compression parameters like Wight variations, hardness, 
friability, disintegration and dissolutions parameters. In vitro dissolution profile of all the nine 
formulations compared with Innovator dissolution profile, from that F1-F6 does not show 
remarkable  Dissolution profile with innovator dissolution profile. F7-F9 shows the 75-95% of 
drug release and match with innovator dissolution profile. Among all the formulations F9 
showing the release profile (96.87%) similar to the innovator. By this evaluation results F9 was 
selected as the best formulation.F9 meet all the criteria specified in IP.The selected formulation 
was stable during the test period of accelerated stability studies. 
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1. INTRODUCTION 
   
                                           Pharmaceutical products designed for oral delivery and 
currently available on the prescription and over the counter markets are mostly the 
immediate release type, which are designed for IR of drug for rapid absorption. 
Disintegrating agents are substance routinely included in tablet formulation to promote 
moisture penetration and dispersion of matrix of dosage form in dissolution fluids1. 
 The oral route of drug administration is the most popular 
and successfully used for conventional delivery of drugs. It offers the advantages of 
convenience, ease of administration, greater flexibility in the dosage form design, ease of 
production, and low cost. The dosage form available for administrations are solutions, 
suspensions, powders, tablet and capsules. The physical state of most of being solids, they 
are administered in solid dosage form. The solid dosage forms provide best protection to 
drugs against temperature, light, oxygen and stress during transportation  2 
1.1 IMMEDIATE RELEASE DOSAGE FORMS 3,4,5,6,7,8 
                                    Immediate release dosage forms are conventional dosage forms 
that allow the drug to dissolve in gastrointestinal tract with no intention of delaying or 
prolonging the drug dissolution or absorption.Immediate drug release dosage forms 
disintegrate rapidly after administration with enhanced dissolution. Immediate release 
may be provided by way of an appropriate pharmaceutically acceptable diluents or carrier 
does not prolong to an appreciable extent, rate of drug release and/or absorption. These 
dosage form usually release (dissolve/disperse) the drug in a single action, which means 
the drug is released initially very quickly and then passes through the mucosal membrane 
in to the body, reaching the highest plasma level in a comparatively short time. Their 
advantage are release the drug  immediately more flexibility in adjusting the dose 
dumping problem and can be used in initial and final stages of diseases. 
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1.1.1 COMPONENTS OF IMMEDIATE RELEASE DOSAGE FORMS 
 Disintegrants and superdisintegrants 
 Lubricants 
 Diluents 
 Flavors and sweeteners 
1.1.2       Merits of immediate release dosage form 
 Improved solubility of pharmaceutical composition 
  Decreased disintegration and dissolution time for immediate release oral dosage 
forms 
 Allows high drug loading 
 Suitable for  controlled/sustained release activities  
 Improved stability and bioavailability 
 Cost effective 
 Improved compliance/added convenience 
 Ability to provide advantages of liquid medication in the form of solid 
preparation. 
 
1.1.3  Some Limitations of immediate release dosage forms 
 
 In conventional oral dosage forms, there is little or no control over the release of 
drug and effective concentration at the target site can be achieved by intermittent 
administration of glossy excessive doses. 
 The dosing pattern in conventional dosage results in constantly changing, 
unpredictable and often sub therapeutic plasma concentration, leading to marked 
side effects in some cases. 
  The rate and extent of absorption of drug from conventional formulations may 
vary greatly, depending upon the factors such as physiochemical properties of the 
drug, excipients, various physiological factors such as the presence or absence of 
food, pH of the gastrointestinal tract, and Gastro intestinal motility.  
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          Figure1: Typical plasma drug concentration – profile for conventional tablet or 
Capsule formulation, a sustained release and an oral controlled release formulation 
 
   1.2    ANTIHYPERTENSIVE DRUGS9, 10 
                    Hypertension (HTN) or high blood pressure sometimes called arterial 
hypertension is a chronic medical condition in which the blood pressure in the arteries 
elevated. This requires the heart to work harder than normal to circulate blood through the 
blood vessels. Blood pressure is summarized by two measurements, systolic and diastolic, 
which depend on whether the heart muscle is contracting (systole) or relaxed between beets 
(diastole).Normal blood pressure at rest is within the range of 100-140mmHg systolic (top 
reading) and 60-90mmHg diastolic (bottom reading).High blood pressure is said to be present 
if it is persistently at or above 140/90mmHg.If this disease control on time, otherwise it may 
lead to heart attack, brain stroke or kidney damage     
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 Hypertension emerged as a major public health problem 
worldwide. There are many factors causing hypertension, some of them occur due to 
heredity, gender (mostly affected in males than females), obesity, age (especially in elder 
persons which may due to hardening of arteries or atherosclerosis),sodium salt sensitivity, 
alcohol use and physical inactivity. 
1.3 AMLODIPINE 11,12 
                       Amodipine is dihydropyridine calcium antagonist, which inhibits the 
transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.It is 
used to treat hypertension, chronic stable angina, and confirmed or suspected vaso-spatic 
angina. 
 Amlodipine is a medication used to lower blood pressure and prevent chest 
pain. By widening blood vessels it lowers blood pressure. In angina, amlodipine increases 
blood flow to the heart muscle to relieve pain due to angina. It can be used either 
monotherapy or combination therapy for the management of hypertension or coronary artery 
disease. Amlodipine can be administered to adults and children 6-17 years of age. 
1.4    Classification of antihypertensives13,14,15           
                                           Antihypertensive are class of drugs that are used to treat 
hypertension (high blood pressure). Antihypertensive are classified based on their chemical 
structure or mechanism of action. 
1. Diuretics 
 Loop diuretics 
 Bumetanide 
 Furosemide 
 Ethacrynic acid 
 Thiazide diuretics 
 Eptizide 
 Hydrochlorothiazide 
 Chlorothiazide 
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 Potassium sparing diuretics 
 Amiloride 
 Triamterene 
 Spiranolactone 
 
2. Calcium channel blockers 
 Dihydropyridins 
 Amlodipine 
 Felodipine  
 Nicadipine 
 Nifidipine 
 Non-dihydropyridins 
 Diltiazem 
 Verapamil 
 
3. ACE inhibitors 
 Captopril 
 Enalapril 
 Ramipril 
 Benzapril 
 Perindopril 
    Quinapril 
 4. Angiotensin II receptor antagonists 
 Telmisartan 
 Candesartan 
 Irbesartan 
 Valsartan 
 Olmesartan 
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 5. Adrenergic receptors 
  blocker 
 Atenolol 
 Metaprolol 
 Nadalol 
 Nebivilol 
 Pindolol 
 Timolol 
 α blocker 
 Doxazosin 
 Phentolamine 
 Prazosin 
 Terazosin 
 Tolazolin 
 
 
 Mixed α+ blockers 
 Carvidilol 
 Labetalol 
 Bucindolol 
6. Vasodilators 
 Hydralazine  
 Sodium nitroprusside 
 
 7. Adrenergic receptor agonists 
 Clonidine 
 Methyldopa 
 Guanfacine 
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1.5 ANTIANGINAL DRUGS16,17 
These drugs are used against angina. These drugs improve the myocardial perfusion and 
decrease the metabolic demand or possessing both the properties. The two main 
categories of drugs that come under these types are:- 
 
               1. ORGANIC NITRATE 
               2. CALCIUM ANTAGONIST ORGANIC NITRATES 
 
1.5.1  Classification of antianginal drugs 
1. Nitrates                      
I. Short acting 
 Glyceryl trinitrate 
 Nitroglycerine 
II. Long acting 
 Isosorbide di nitrate 
  Isosrbide mono nitrate 
 Erythrytyl tetra nitrate 
 Penta erythritol tetra nitrate 
2.  blockers 
 Metaprolol 
     Propranolol 
    Atenalol 
3. Calcium channel blockers 
I. Phenyl alkylamines 
     Verapamil 
II. Benzothiazepines 
 Diltiazem 
III. Dihydropyridines 
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     Nifedipine 
     Amlodipine 
     Felodipine 
 4.Pottassium channel openers 
 Nicorandil 
 penacidil 
5. Others 
   Dipyridamole 
 Trimetazidine 
1.5.2  The mechanism of antianginal drugs 
1. Decrease myocardial oxygen consumption 
2. Increase myocardial blood and oxygen supply 
3. Antiplatelet ,Antithrombosis 
 
1.5.3  Calcium channel blockers: mechanism of anti angina 
 
1. Dilate coronary arterial 
2. Reduction in peripheral vascular resistance 
3. Negative chronotropic and inotropic, 
Decrease myocardic oxygen consumption 
4. Protect cardiac myocytes 
5. Anti atherosclerosis 
1.6 TABLETS 17,18 
 Tablets are solid preparations is containing a single dose of one or more active 
substances and usually obtained by compressing uniform volume of particles. Tablets are 
intended for oral administration. Some are swallowed whole, some after being chewed, some 
are dissolved or dispersed in water before being administered and some are retaining in 
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mouth where the active substances liberated. The particle consisting of one or more active 
substance with or without  excipients  such as diluents, binders, disintegrating agents , 
glidants,lubricants, substance capable of modifying the behavior of the preparation in the 
digestive tract colorings matter authorized by the competent authority and flavoring 
substance. 
 1.6.1       Advantages of tablets19, 25, 26 
 They are unit dosage form and they offer the capabilities of all oral dosage forms for 
the dose precision and the least content variability during dosing. 
 Accuracy and uniformity of content 
 Optimal drug dissolution and hence,availability from the dosage form for absorption 
consistent with intended use(ie. immediate or extended) 
 Usually taken orally, but can be administered sublingually,rectally or intra vaginally 
 Their cost is lowest of all oral dosage forms 
 They are the most compact of all oral dosage form 
 Organoleptic properties are best improved by tablet coating. 
 Easy to administer does not require a specialist. 
 They are better suited to large scale than other unit oral forms. 
 Ease of packaging (blister or strip) and easy handling over the liquid dosage forms. 
 Product identification is easy and markings done with the help of grooved punches 
and printing with edible ink. 
 
 1.6.2   Disadvantages of tablets27 
 Some drugs resist compression, due to their amorphous nature or low density. 
 Chance of G I irritation caused by locally high concentrations of medicament. 
 Difficulty in swallowing tablets in small proportion of people and so size and shape 
become important considerations. 
 Drugs having bitter taste, objectionable odour or drugs that are sensitive to oxygen 
may require encapsulations or coating of tablet. 
 Bioavailability problems. 
 Difficulty for kids, terminally ill and geriatric patients. 
 Slow onset of action compared to parenterals and solutions 
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 1.7   Types and Classes of tablets 18,19,20,24 
                            Tablets are classified by their routes of administration  
A. Oral tablets  for ingestion 
 Compressed tablets or standard compressed tablets 
 Multiple compressed tablets 
a) Layered tablets 
 
b) Compression coated tablets 
 Repeat action tablets 
 Sustained release or modified release tablets 
 Delayed action or enteric coated tablets 
 Film coated tablets 
 Chewable tablets 
B. Tablets used in oral cavity 
 Buccal tablets 
 Sublingual tablets 
 Trouches and lozenges 
 Dental cones 
 
C. Tablets administered by other routes 
 Implantation tablets 
 Vaginal tablets 
D. Tablets used to prepare solutions 
 Effervescent tablets 
 Dispersible tablets 
 Hypodermic tablets 
 Tablets triturates 
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1.8 FORMULATION OF TABLET22, 23, 24, 28 
 Tablet generally consists of mixture of active pharmaceutical ingredients and 
excipients. Excipients mean any component other than active pharmaceutical ingredients. 
While selecting excipients for any formulation following should be considered. 
 Keep the excipients to a minimum in number 
 Minimize the quantity of each excipients 
 Multi functional excipients may be given preference 
over unifunctional excipients.  
1.9 ROLE OF EXCIPIENTS IN SOLID DOSAGE FORM29 
A.DILUENTS OR FILLERS 
                              Diluents are added the quantity of active ingredients is small or difficult to 
compress.Eg: sucrose, lactose, starch 
B.BINDERS OR GRANULATING AGENTS 
 Binders help powders fuse or link particle to another.Eg: starch, povidone 
C.DISINTERGRANTS 
 Disintegrates help the tablet breaks up after the patients ingest it.Eg: sodium 
starch glycolate, starch 
D.LUBRICANTS 
 Lubricants prevent powders from sticking to the metal component of the tablet 
press and tablet press tooling.Eg: starch, magnesium stearate 
 
D.GLIDANTS 
 Glidants are agents that are added to the tablet formulation. In order to improve 
the flow properties of granulation. They act by reducing inter particulate friction.  
Eg: magnesium stearate, talc. 
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E.ADSORBENTS 
                      Adsorbents are the substances included in the formulation that are capable of 
holding quantities of fluid in an apparently dry state. Oil soluble drugs, fluid extractor or oil 
can be mixed with adsorbents and then granulated and compressed into the tablet. Eg: 
magnesium carbonate, fumed silica 
 
F.COLORANTS 
                       Colorants are often added to tablet formulation to add value or for product 
identification. 
 
G.PRESERVATIVES      These are the substances used to preserve food stuffs, wood, 
or other materials against decay Eg: methylparaben, propylparaben 
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Table no:1 Steps involved in tablet manufacturing process 
 
 
S.NO PROCESSING 
STEPS 
DIRECT 
COMPRESSION 
WET 
GRANULATION 
DRY 
 GRANULATION 
1 RAW 
MATERIALS 
YES YES YES 
2 WEIGHING YES YES YES 
3 SCREENING YES YES YES 
4 MIXING YES YES YES 
5 COMPRESS YES NO  YES 
6 WET MASS NO  YES NO 
7 MILLING NO  NO YES 
8 DRYING NO YES NO 
9 SHIFTING NO YES YES 
10 MIXING NO YES YES 
11 COMPRESSION NO  YES YES 
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1.10) STABILITY STUDIES AS PER ICH GUIDELINES30,31 
 Stability is essential factor of quality,safety ad efficacy of drug 
product .In theory stabilityof pharmaceutical preparation should be evaluated by exposing the 
product to normal shelf life conditions for year of extended periods.Generally the rate of 
decomposition is slow at room temperature.So such a method  is time consuming and 
uneconomical.Therefore in practice methods are devised to accelaratethe rate of degradation 
by keeping the products at higher temperatures.Accelarated stability studies are used to 
predict the shelf life of product by accelerating the rate of decomposition ,preferably by 
increasing the temperature. 
 Stabity testing provides evidence that the quality of drug substance 
change with time under the influence of various enviormental conditions such as temperature 
, relative humidity etc.Stability studies consist of a series of test inorder to maintain an 
assurance of stability of drug product,namely maintenance of drug product packed in 
specified packaging material and stored in established storage conditions within the 
determined time period. 
 
 
 
 
 
 
 
 
 
 
                           Aim and objective 
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 AIM OF STUDY 
                             
Developing a new formula for the Amlodipine tablet IP 5mg immediate release film 
coated tablets, by evaluation of trial formulations and invitro dissolution profile. 
  
 
 OBJECTIVE OF STUDY 
  Carrying out literature survey of the drug molecule. 
  Formulation of the tablets using different trials. 
  Analyzing the trial samples. 
  Optimizing the final formula. 
Plan of work 
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3. PLAN OF WORK 
 Development of final formula 
 
 Literature collection of trial product. 
 
 Preformulation studies. 
 
 Determination of Drug polymer Compatibility. 
 
 
 Formulation of trial products. 
 
 Dissolution studies of  formulations. 
 
 Comparison of Dissolution profile of trials with innovator. 
 
 Finalization of quantitative formula. 
Literature review 
 
R.V.S College of Pharmaceutical Sciences Page 17 
 
4. LITERATURE REVIEW 
 Rajalekshmi.R٭, Senthilkumar.M, Valamathi.S et al (2012)57. , To develop a stable 
formulation of antihypertensive drug of Telmisartan and Amlodipine Besylate as an 
immediate release bilayer tablet. The basic aim of the study is the need to develop 
proper medications that control hypertension for a longer period of time. Amlodipine 
besylate is a long acting calcium channel blocker used in the treatment of chronic 
stable angina, vasospatic angina, and hypertension.Telmisartan is a potent, long acting 
,non peptide antagonist of Angiotensin II(AT1) receptor blocker , which is indicated 
for the treatment of hypertension.It blocks the vasoconstrictor and aldosterone – 
secreting effect of  Angiotensin II. A total number of nine formulations have been 
taken to optimize and develop a robust and a stable formulation .Among the 
formulation tablet F9 showed satisfactory physical parameter and found to be stable. 
The optimized formulation F9  had 96.68% of drug release for telmisartan layer and 
95.73% drug release for Amlodipine layer.the results suggest that the feasibility of  
developing bilayer tablets with two drugs Telmisartan and Amlodipine Besylate for 
the convenience of patients with severe hypertension. 
 N.Narasimha Rao*,B. Radha Krishna Murthy,D.Rajasekhar et al(201358., Has 
study the design and development of Amlodipine besylate fast dissolving tablet using 
natural super disintegrants.Amlodipine is sparingly soluble orally administered drug 
and the rate of absorption is often controlled by the rate of dissolution.The rate of 
dissolution can be increased by incorporating the drug in a fast disintegrating  dosage 
form.Mucilage of natural origin is preffered over semisynthetic and synthetic 
substances .In this study they were developed the fast dissolving tablets of 
Amlodipine Besylate, using different concentrations of  natural super disintegrating 
agents like Fenugreek seed Mucilage, Treated Agar, Modified tragacanth.From this 
study the concluded the Modified tragacanth shows the excellent super disintegrant 
prpperty and treated agar gum shows better super disintegrant property .Fenugreek 
seed used as disintegrant shows less disintegrant property in the formulation of fast 
dissolving tablets when compared to other natural polymers. 
 M.Manikandan, K.Kannan*,S.Thirumurugu et al(2012)59.,  Has study the design 
and evaluation of Amlodipine besylate and Atorvastatin calcium tablets.Amlodipine 
Besylate is a calcium channel blocker and used for treating high blood pressure and 
certain types of angina and coronary heart failure.Atorvastatin calcium known as 
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statin used for lowering blood cholesterol and in the treatment of primary 
hypercholesterolemia and dyslipidemia.The main objective of this study was to 
formulate and evaluate an oral administerable tablet containing Amlodipine Besylate 
and atorvastatin calcium  by wet granulation method .Among all the 4 formulations 
,F4 formulation was better in all the terms of Precompression and post compression 
parameters. No significant change in the drug content ,physical properties and 
dissolution rate of the tablets after the storage of 3months at 250c&60%RH and 
400c&75%RH.This study concluded that the combined pill has the potential to 
improve the management of hypertensive patients with additional cardiovascular risk 
factors. 
 Prakash Babu Dahal٭, R.Sambath kumar, K.Jaganathan, et al (2014)60.,has been 
made for the development of rapidly disintegrating tablets of Amlodipine besylate by 
solid dispersion technique.six solid dispersion has been prepared in different carrier 
formulations ratios.Dissolution study has been done for all six solid dispersion and  
among the best solid dispersion has been selected and used for the tablet 
formulation.In this study ,fast disintegrating tablet were prepared by using the 
different super disintegrants like crospovidone,cross caramallose sodium,Agar and 
guar gum . The effect of various superdisintegrants  on disintegration behaviour of 
tablets was evaluated in phosphate buffer PH 0.01 N HCL.All the formulations were 
evaluated for the pre compression and post compression parameters. Wetting time of 
the formulations containing Crosspvidone and Agar was least and tablet showed 
fastest disintegration.FT-IR studies revealed that thre is no physio chemical 
interaction between Amlodipine Besylate and other exicipients.Amongst all the 
formulations F6 prepared by both the combination of crospovidone and Agar showed 
least disintegrating time and faster dissolution of 98.04%. 
 Avinash Mahatme1,Vijay R. Mahajan1,V.R Gudsoorkar2,et al(2015)61.,has study the 
formulation and evalution of immediate release tablet of Amlodipine Besylate.The 
FT-IR study was also conducted and there is no iteraction between the drug and the 
exicipients.The immediate release tablet was prepared by using the exicipients like 
SSG,Cross povidone,Cross caramallose by wet granulation method.Thus the prepared 
A4 batch of Amlodipine containing higher concentration of SSG ie. 10% released 
95.98% drug within 1hrs. Stability data of optimized batch of tablets revealed that 
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there were no changes observed in the appearance , drug content, dissolution profile 
which showed that immediate release tablet is stable at 40±20c/75±5%RH. 
 Behin sundara raj et al(2012)62 .,has study the formulation and characterization of 
fast disintegrating  tablets of Amlodipine using super disintegrants by direct 
compression method.crospovidone and sodium starchglycolate as 
thesuperdisintegrants.combination of both superdisintegrant shows least  
disintegration time and faster dissolution of 87%.combination of super disintegrant is 
better suited for the development of fast disintegration tablet. 
 Methaq.H.Sabar et al (2013)63.,Has study the preparation and invitro evaluation of 
fast dissolving film of amlodipine besylate solid dispersion ,and the release increased 
with increasing the ratio of PEG 6000 or PVP in solid dispersion increased the release 
rate and the solvent evaporation method gave greater release than the fusion 
method.In fast dissolving film it was seen that the concentration of SCMC increased 
the release rate and decrease significantly and as the concentration of glycerin 
increased the release rate increased significantly. 
 Jaimin Modi et al (2016)64.,has study the formulation evaluation &optimization of 
immediate release tablet of fexofenadine hydrochloride .the invitro dissolution studies 
show the release in following order of super disintegrants.cross caramallose>sodium 
starch glycolate.Drug release mechanism in all media(PH1.2,PH4.0,PH6.8)was found 
as diffusion controlled.(ie.,n value-0.219 to 0.042).Higuichi square root law indicates 
the drug release follows diffusion release mechanism. 
 Anjum et al (2014)65.,has study the assessment of pharmaceutical quality control and 
equivalence of various brands of amlodipine besylate (5mg)tablets available in the 
Pakistani market under biowaiver conditions.dissolution test done in various medias 
(Distilled water,PH 1.2, PH 4.5,PH6.8).Under biowaiver conditions all the generics are 
interchangable with innovator;they are therapeutically equivalent. 
 Oyeniyi et al(2016)66.,has study the comparative pharmaceutical evaluation of 
amlodipine (5mg)tablets registered in Nigeria by NAFDAC,and marketed by various 
pharmaceutical companies nationwide.All the brands evaluated achieved 85% release 
of the active ingredient within 30 min,in all the dissolution media with PH1.2,4.5,6.8 
and the release of all the brands are similar at various PH values used. 
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 S.Suresh et al(2011)67.,has study the formulation and evaluation mouth dissolving 
tablet of Amlodipine besylate by using the threesuper disintegrants 
viz.,hypromellose,crospovidone and sodium starch glycolate at different concentration 
with microcrystalline cellulose.Among three super disintegrants crospovidone F7 
emerged as overall best formulation. 
 
 Soham shukla et al(2013)68.,has study the formulation,optimization and evaluation of 
immediate release bilayer tablet of Temisartan and amlodipine besilate using full 
factorial design.TF6was optimized in telmisartan layer which contained meglumine 
7.5%(16mg)and crospovidone 5%(11mg)and AF7was optimized in amlodipine layer 
which contained starch paste 5%(5mg)and croscaramallose sodium 3%(3mg). 
 
 Shoba krushnan et al (2016)69.,has study the formulation and evaluation of 
orodispersible tablet of amlodipine besilate.Formulation containing higher 
concentration of sodium starch glycolate and crospovidone as superdisintegrant 
showed better dissolution profile and disintegration time.FT-IR and DSC were 
conducted for drug exicipients compatibility study. 
 
 Mayur et al (2013)70.,has study the immediate release tablet of antihypertensive drug 
olmesartan medoxomile. Effect of different fillers and disintegrants were also 
explored . microcrystalline cellulose ,lactose monohydrate,were used in wet 
granulation.final selection of the formula based on the pharmaceutical equivalence of 
developement formulation to that of marketed one. 
 
 Narmada G Y et al(2009)71.,Has study the formulation evalution and optimization of 
fast dissolving tablets containing amlodipine besylate by sublimation 
method.Sublimation method was adopted to prepare the tablets using 23 fullfactorial 
design.FT-IR and DTA conducted for the compatibility of drug with exicipients.The 
results obtained showed that the quantity of starch potato, sodium starch 
glycolate,camphor significantly affect the response variables. 
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 Nyol et al(2013)72.,has done a review related to the immediate release dosage forms 
for fulfill the medical needs ,formulators have devoted considerable effort to 
developing novel type of tablet dosage form for oral administration ,one that 
disintegrates and dissolve  rapidly with enhanced dissolution.An extension of market 
exclusivity ,which can be provided by immediate release dosage form,leads to 
increased revenue,while also targeting undeserved and under-treated patient 
populations. 
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5. DRUG AND EXICIPIENTS PROFILE 
5.1 DRUG PROFILE 
5.1.1AMLODIPINE DRUG PROFILE32,33,34,37 
                             Figure No: 2 structural formula 
 
 
 
Table No: 2 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Properties 
 
Information 
Molecular Formula 
 
C20H25ClN2O5 
Molecular weight 
 
408.879 g ̸ mol 
IUPAC 3 Ethyl 5 Methyl 2-[(2-Aminoethoxy]-4-(2-
chlorophenyl)-6-Methyl-1,4-Dihydropyridine-
3,5Dicarboxylate 
Macroscopic Appearance 
 
White crystalline powder 
Half life 30-50 hours 
 
Solubility Water-slightly soluble 
Methanol-freely soluble 
Ethanol-sparingly soluble 
2- propanol-sligtly soluble 
pH 1-6 at  370 C 
 
pKa 8.6 
 
Use Anti hypertensive,anti anginal 
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5.1.2 MECHANISAM OF ACTION OF AMLODIPINE35, 36 
 Pharmacokinetically it is the most distinct Dihydropyridines 
(DHP).They lower Bp by decreasing peripheral resistance without compromising cardiac 
output .Despite vasodialation, fluid retention is insignificant. Also inhibit transmembrane 
influx of calcium ions into vascular smooth muscles and cardiac muscles.It is indicated for 
the treatment of hypertension, chronic stable angina, and confirned or suspected vasospatic 
angina. 
              Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-
channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth 
muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both 
dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac 
muscle and vascular smooth muscle are dependent upon the movement of extracellular 
calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion 
influx across cell membranes selectively, with a greater effect on vascular smooth muscle 
cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such 
effects have not been seen in intact animals at therapeutic doses. Serum calcium 
concentration is not affected by Amlodipine. Within the physiologic pH range, Amlodipine is 
an ionized compound, and its kinetic interaction with the calcium channel receptor is 
characterized by a gradual rate of association and dissociation with the receptor binding site, 
resulting in a gradual onset of effect. 
Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to 
cause a reduction in peripheral vascular resistance and reduction in blood pressure. 
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5.2 EXCIPIENTS PROFILE 
                                                               5.2.1 STARCH38 
Table No:3 starch excipient profile 
  
 
Non proprietary 
Names 
 
 
Amylum,Polysaccharide 
 
 
Synonyms 
 
 
Starch1500,Starch LM 
 
Empirical formula 
 
 
(C6H10O5)n 
 
Molecular weight 
 
 
Depends on extent of gelatinization 
 
Description 
 
 
White color, tasteless 
 
Functional 
categories 
 
Thickening agent, stiffening agent, gluing agent 
 
Solubility 
 
 
Insoluble in cold water or alcohol, Becomes soluble in water on heating 
 
Stability and 
storage condition 
 
 
Starch is stable and should be stored in a well closed container in a cool 
,dry place 
 
Incompatibilities 
 
 
Incompatible with strong acids,alkali.Avoid mixing with strong 
oxidizing agents 
 
Applications 
 
 
Binder, Disitegrant, Flow aid, Lubricant 
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5.2.2 SODIUM STARCH GLYCOLATE39 
Table No: 4 sodium starch glycolate excipient profile 
 
Non proprietary 
Names 
 
Explotab,Vivastar 
 
Synonyms 
 
 
Sodium salt ofcarboxymethyl ether of  starch 
 
Empirical 
formula 
 
 
C2H5ONa 
 
Molecular 
weight 
 
 
500000-11000000 
 
Description 
 
 
White to off- white, Tasteless, odorless, relatively free flowing powder 
 
Functional 
categories 
 
 
Disintegrant, Dissolution aid, Suspending agent 
 
Solubility 
 
 
Practically insoluble in organic solvents. Absorbs water rapidly 
 
Melting point 
 
 
3380C 
 
Stability and 
storage 
conditions 
 
 
 
Store in well closed container to protect from humidity 
 
Incompatibilities 
 
 
Mostly compatible with all other tableting ingredients 
 
Applications 
 
 
Suspending and gelling agent 
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5.2.3 LACTOSE40 
Table No: 5 Lactose excipient profile 
 
Non- proprietary 
Names 
 
 
Lactose monohydrate ph Eur: 
Lacto sum(BP) 
Lactose monohydrase(USP) 
 
Synonym 
 
 
Fast-flo,Lactohem, Microtose, Pharmatose 
 
Empirical 
formula 
 
 
C12H22O11.H2O 
 
Molecular 
weight 
 
 
360.31 
 
Description 
 
 
White off white to crystalline particles or powder. Odorless and slightly sweet 
tasting 
 
Functional 
categories 
 
 
Tablet and capsule diluents 
 
Solubility 
 
 
Freely soluble in water 
 
Melting point 
 
 
201-2020C 
 
Stability and 
storage 
conditions 
 
 
Under humid conditions (80% relative humidity and above), mold growth may 
occur. Lactose may develop a brown coloration on storage. Lactose should be 
stored in a well closed container in a cool, dry place. 
 
Incompatibilities 
 
 
Lactose incompatible with aminoacids,aminophylline,amphetamine 
 
Applications 
 
 
Filler or diluents, Binder 
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                                                      5.2.4 TALC41 
TableNo: 6 Talc excipient profile 
 
Non proprietary 
names 
 
 
B.P – purified talc 
JP-Talc 
Ph Eur-Talcum 
USP-Talc 
 
 
Synonyms 
 
 
At talc, Hydrous magnesium calcium silicate, Hydrous magnesium 
silicate,Magsil osmanthus,Purified French chalk 
Magnesium hydrogen meta silicate,soapstone 
 
Empirical formula 
 
 
Mg3Si4O10(OH)2 
 
Molecular weight 
 
 
379.27 
 
Description 
 
 
Talc is very fine, white to grayish white, odorless, unctuous, crystalline 
powder. It adhere rapidly to the skin and is soft to the touch and free 
from grittiness 
 
 
Melting point 
 
 
1500C 
 
Solubility 
 
 
Not soluble in water and slightly soluble in dilute mineral acids, 
insoluble in  water and ethanol 
 
Functional 
categories 
 
 
Anti caking agent,glident,diluents and  lubricant for tablets and 
capsules 
 
Stability and 
storage conditions 
 
 
Talc is stable material and may be sterilized by heating at 1600c for not 
less than 1 hour. It may also be sterilized by exposure to ethylene oxide 
or uv radiations. Talc should be stored in a well closed container in a 
cool, dry place. 
 
Incompatibilities 
 
 
Incompatible with quaternary ammonium compounds 
 
Applications 
 
 
Lubricant, Diluent,dissolution retardant in controlled release 
formulations 
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5.2.5 MAGNESIUM STEARATE39 
Table No: 7 Magnesium stearate excipient profile 
 
Non proprietary 
names 
 
BP-Magnesium stearate 
JP-Magnesium stearate 
PhEur-Magnesium stearate 
 
Synonyms 
 
Dibasic magnesium stearate;Magnesium distearate;Magnesium 
octadeconoate;octadecanoic acid; Magnesium salt 
 
Empirical 
formula 
 
 
C36H70MgO4 
 
Molecular 
weight 
 
 
591.24 
 
Description 
 
 
Magnesium stearate is very fine, light white, precipitated or milled, 
impalpable powder with low bulk density, having a faint odor of stearic 
acid and a characteristic taste. The powder is greasy to the touch and 
readily adheres to the skin. 
 
 
Functional 
categories 
 
 
 
Tablet and capsule lubricant 
 
Solubility 
 
Practically insoluble in ethanol (95%), ether and water, slightlysoluble in 
warm benzene and warm ethanol (95%). 
 
Melting point 
 
 
117-1500C 
Stability and 
storage 
conditions 
Magnesium stearate stable and should stored in a well closed container in 
a cool, dry place 
 
Incompatibilities 
 
 
Incompatible with strong acids,alkalies,andiron salts.Avoid mixing with 
strong oxidizing materials 
 
Applications 
 
 
It is primarly used as lubricants in tablet and capsule manufacture 
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                                                  5.2.6 METHYL PARABEN42 
TableNo:8 Methyl paraben excipient profile 
 
Non proprietary 
names 
 
Sodium methyl para hydroxyl benzoate, methyl paraben sodium salt 
 
Synonyms 
 
 
Methyl 4-OH benzoate,NipaginM 
 
Empirical 
formula 
 
 
C8H8O3 
 
Molecular 
weight 
 
152.14732 
 
Description 
 
 
Colorless crystals or white crystalline powder 
 
Solubility 
 
 
Soluble in water at 250C, slightly soluble in benzene,CCl4,ehanol,ether, 
acetone,DMSO,methanol 
 
Stability and 
storage 
conditions 
 
 
Stable at ambient temperature and under normal condition of use dust may 
be explosive. 
Store in a cool dry and well ventilated place,keep container closed when 
not in use. 
 
Melting point 
 
 
125-1280C 
 
Functional 
category 
 
Preservative 
 
Incompatibilities 
 
 
Incompatible with alkalies and metal salt 
 
Application in 
pharmaceutical 
industry 
 
 
It is an antifungal agent, often used in variety of cosmetics and personal 
care products. It is also used as food preservative. Fungicide in Drosophila 
food media 
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                                                    5.2.7 PROPYL PARABEN43, 44 
Table No: 9 propyl paraben excipient profile 
 
Non proprietary 
names 
 
 
Propylis  parahydroxybenzoate (Latin) 
Propyl 4- hydroxybenzoat (German) 
Propyle(parahydroxybenzoate de) (French) 
 
 
Synonyms 
 
Propyl butex,Propyl chemosept, Propyl 4-OH benzoate, 
Propyl Para-OH benzoate, Para OH benzoic acid propyl ester 
 
Empirical 
formula 
 
 
C10H12O3 
 
Molecular weight 
 
 
180.2 
 
Description 
 
 
White crystalline powder ,colorless crystsls or white powder or chunky 
white solid,odorless or faint aromatic odour,low toxicity and tasteless 
 
 
Solubility 
 
 
Water soluble 
 
Melting point 
 
 
95-980C 
 
Stability and 
storage conditions 
 
 
Stable, stability maximum occurs at pH  4-5 
 
Functional category 
 
 
Preservative ,food additive 
 
Incompatibility 
 
 
Incompatible with alkalies and metal salts 
 
Application in 
pharmaceutical 
industry 
 
 
An antimicrobial, Preservative in packaged foods, pharmaceuticals, 
cosmetics,  personal care products 
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6. METHODOLOGY 
6.1 PRE- FORMULATION STUDIES 45,46,47, 48,49 
Preformulation studies is an investigation of physical and chemical properties  of a drug 
substance alone or  in combination with exicipients. It is the first step in the rational 
development of the dosage forms. 
A) Physiochemical evaluation of a drug molecule 
 
1) Description 
 
2) Solubility 
 
 
3) PH 
 
4) Melting point 
 
5) Chemical nature 
 
6) Hygroscopicity 
 
7) Loss on drying 
 
8) Particle size determination 
 
9) Flow properties 
 
B.Compatibility studies of the drug molecule with excipients 
                           The information obtained from preformulation studies indicates many of the 
subsequent events and approaches to be taken into consideration during formulation 
development. It is imperative to ensure the ingredients used are compatible with one another. 
Incompatibility occurs between the drug and excipients and the excipients themselves. 
Incompatibilities manifested through many modes, such as acid base interaction and complex 
formation, result in lower potency or stability and eventually, poor therapeutic efficacy of the 
product .Therefore it is essential to avoid incompatibilities, and this is achieved by carrying 
out studies to detect potential interactions between the components used in the formulation. 
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A.PHYSIOCHEMICAL PARAMETERS 
1)Description 
 Atypical preformulation study should begin with the description of the 
drug substance.ie the color, odour and taste of the new drug must be recorded.It kept as 
reference for comparing with the other batches during the production. 
 2) Solubility 
                            Preformulation studies focuses on drug solvent system that could occur 
during delivery of the drug molecule. So understanding the solubility profile of drug regarded 
as the one of the most important aspect of preformulation testing, especially for those drugs 
which are administered as oral dosage forms,parenterals and also the drugs which are 
unstable on contact with solvent.Solubility is related to the strength of solute-solvent bond 
strength and interaction between the solute and the solvent. 
 3) pH 
 The pH is the measure of negative logarithm of hydrogen ion concentration of 
an aqueous solution. It is one of the most important factors from which the stand point of 
solubility, stability and physiochemical suitability of a formulation. The pH value of a 
solution is determined potentiometrically by means of a glass electrode.  
 4) Melting point 
 A temperature at which the first particle of the substance completely melts 
is regarded as melting point of the substance, and also at which the first particle starts to melt 
and last particle completely melts is regarded as the melting range 
 5) Chemical nature 
 Solubility, stability, bio availability etc., a substance is depends on 
its chemical nature and this information helps to design a suitable dosage form 
   6) Hygroscopicity 
 It is defined as ability of a substance to absorb moisture from the 
environment it exposed 
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Table No: 10 Moisture absorption analysis 
 
S.NO NATURE OF SAMPLE RESULT OF THE DETERMINATION 
 
 
 
1 
 
 
Deliquescent 
 
Sufficient water absorbed to form a liquid 
 
2 
 
Very hygroscopic 
 
 
Increase in mass equal to or more than 15% 
 
3 
 
Hygroscopic 
 
Increase in mass less than 15% and equal to or more 
than 2% 
 
 
4 
 
Slightly hygroscopic 
 
Increase in mass less than 2% and equal to or more than 
0.2% 
 
 
 
7) Particle size determination 
 Particle size determination is an important factor which determines 
number of parameters like dissolution rate, bioavailability, content uniformity, flow 
properties, texture and stability of a formulation. The particle size can be analyzed by number 
of methods like sieving,  optical microscopicy, and laser diffraction methods .The particle 
size of Amlodipine analyzed by sieving method 
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Sieve analysis 
Table No: 11 Classification of sample based on the % of sample retained or passed on test 
sieve. 
S.NO NATURE OF SAMPLE RESULT OF DETERMINATION 
1  
Coarse powder 
NLT 95%of the sample mass pass through 14# 
And NMT40% pass through 36# 
2  
Moderately coarse powder 
NLT 95%of the sample mass pass through 25# 
and NMT40% pass through 60# 
3  
Moderately fine powder 
NLT 95% of the sample mass pass through 
36# and NMT40% pass through 100# 
4  
Fine powder 
NLT 95% of the sample mass pass through 
100 # and NMT 40% pass through 150#   
5  
Very fine powder 
NLT 95% of the sample mass pass through 
150# and NMT 40% pass through 200# 
6  
Super fine powder 
NLT 90% by number of particle are less than 
10µm 
 9) Flow property measurement 
    It is a very important parameter affects the mass uniformity of the dose .Usually flow                
properties are predicted interms of angle of repose, bulk density, and tapped density. 
ANGLE OF REPOSE  
  The angle of repose has been used to characterize the flow properties of solids. It is related 
to inter particulate friction or resistance to movement between particles.It is the maximum 
angle possible between surface of the pile of powder or granules and the horizontal plane.       
                                           θ = Tan-1 h ̸ r 
Where               
                      θ =angle of repose 
                      h =height of the pile 
           r =radius 
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 Method: a funnel was fixed at a height approximately of 2-4 cm over the platform. The 
loose powder was slowly passed along the wall of funnel, till the cone of powder formed. 
Determine the angle of repose by measuring the height of the cone of powder and radius of 
the heap of the powder. 
Table No: 12 flow properties and corresponding angle of repose 
S.No FLOW PROPERTY ANGLE OF REPOSE 
1 Excellent 25-300 
2 Good 31-350 
3 Fair 36-400 
4 passable 41-450 
5 Poor 46-550 
6 Very poor 56-650 
7 Very very poor >660 
 
Bulk density (BD) and tapped density (TD) 
                 Bulk density of a compound varies substantially with the method of  
crystallization, milling or formulation. It is of great importance in case of the tablet and 
capsule manufacturing process, especially in size of a high dose capsule product or the 
homogeneity of low dose formulations in which there is a large difference in drug and the 
excipients densities. In addition to the bulk densities, there is desirable to know the true 
density of the powder for computation of void volume or porosity  of packed powder beds 
 An accurately weighed quantity of powder poured to a graduated 
measuring cylinder and volume measured. Graduated cylinder closed with a lid and and set in 
to the tap density tester. After the volume measured and continued the operation till the two 
consecutive reading where equal. The bulk density and tapped density were calculated by the 
following formulae 
 
Bulk density=weight of the sample in gram ÷volume occupied by the sample 
 Tapped density=Weight of the sample in gram ÷Tapped volume 
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Compressibility index (CI) and Hausner’s (HR) ratio 
              The compressibility index and Hausner’s ratio are used for predicting powder flow 
property .Both the compressibility index and Hausner’s ratio were determined by using the 
bulk density and tapped density of the powder 
             
Compressibility index= tapped-untapped*100 ÷ tapped 
H.R= tapped density ÷ bulk density 
 
Table No: 13 Relation of flow property with Hausner’s ratio & compressibility index  
Compressibility index 
 
Flow property Hausner’s ratio 
≤ 10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very very poor >1.60 
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6.2 MATERIALS AND EQUIPEMENTS 
Table No: 14 List of materials for preparation of Amlodipine tablets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
S.NO Name of Materials used 
 
 
Specification Use 
1 Amlodipine 
 
 
IP Active ingredient 
     2 Starch 
 
 
IP Disintegrant 
    3 
 
Sodium starch glycolate 
 
 
IP Super disintegrant 
    4 Magnesium stearate 
 
 
IP Lubricant 
5 
 
Talc 
 
 
IP Filler or diluent 
6 Lactose 
 
 
IP Glidant 
7 Methyl paraben 
 
 
IP Preservative 
8 Propyl paraben 
 
 
IP Preservative 
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Table No: 15 List of equipment used in formulation and evaluation of Amlodipine Tablets 
 
 
 
 
 
 
S.NO INSTRUMENTS USED 
 
MANUFACTURER 
1. Electronic weighing balance Mettler,Switzerland 
 
2. Electronic weighing balance 1kg Avery India 
 
3. Max mixer Innofab india pvt limited 
Hyderabad 
4. Fluidized bed dryer 
 
Alliance Bombay 
5. Cad mill 
 
Cadmach Ahmadabad 
6. Blender 
 
Bhuvaneswari,Chennai 
7. Tablet compression machine 45 station double 
rotary 
Cadmach Ahmadabad 
8. Friability tester 
 
Veego Mumbai 
9. Tablet hardness tester 
 
Electrolab ,Mumbay 
10. Bulk density apparatus 
 
Elecrolab Mumbay 
11. Dissolution apparatus USPII 
 
Veego,Mumbay 
12. Tablet disintegration apparatus 
 
Veego ,Mumbay 
13. FT-IR spectrophotometer 
 
Perkin elmer,USA 
14. HPLC 
 
Shimadzu,Mumbai 
15. 
 
Tray dryer Gansons,Chennai 
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6.3 PROCESS INVOLVED IN TABLET PRODUCTION 
        Figure No: 3 Flow chart of process involved in tablet production 
                     
                  DRUG                                                         EXCIPIENTS 
 
                                     SIEVING AND WEIGHING 
 
                                                DRY MIXING 
  
                                      BINDER PREPARATION 
 
                                        WET GRANULATION 
 
 DRYING 
  
                                           PULVARISATION 
 
 LUBRICATION 
 
                                               
                                             COMPRESSION 
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Steps involved in amlodipine granules 
Amldipine granules for tablets production are prepared by the following steps 
Dry mixing: Check the weight of amlodipine and sift through the 12 #and load in a Max 
mixer and dry mix for 10 minutes at a low speed 
 
Granulation: Add binder solution in the above powder which mixing for 5-10 min at slow 
speed. Change mill speed to fast and mix for 5-15 minutes till required end point achieved. 
Add excess amount of water if it is required. After mixing of powder scrap material from the 
Max mixer and mill the wet mass through Cad mill load in the bowl of the Fluidized bed 
dryer.  
 
Drying: dry the wet milled granules in tray dryer for  6 hours at 600C . Dry till the loss on 
drying achieved. 
  
Pulverization: Dried granules from the tray dryer is passed through the Cad mill for the size 
reduction.After getting the uniform sized particles passes through respective mesh for the size 
uniformity. Collect the granules in a container and load in a double cone blender. 
 
Blending: Load the granules in octagonal blender and blend for 5 minutes at an rpm speed. 
And sift the sodium starch glycolate and magnesium stearate , talc, lactose through the 40# to 
the blender and blend for 5 minutes 
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6.4 Formulation development comparative data of Amlodipine Ip 5mg immediate 
release film coated tablets(n=9) 
Table no.16 Formulation development comparative data of Amlodipine IP 5mg  film coated 
tablets.  
S.No Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
 
 
1 
 
 
Amlodipine 
(mg) 
7 7 7 7 7 7 7 7 7 
2 
 
 
Starch 
(mg) 
45 50 55 45 50 55 45 50 55 
3 
 
 
Sodium 
starch 
glycolate(mg) 
- - - 1 2 3 1 2 3 
4 
 
 
Lactose 
(mg) 
39.4 34.4 29.4 41.4 35.4 29.4 38.4 32.4 26.4 
5 
 
 
Talc 
(mg) 
5 5 5 5 5 5 5 5 5 
6 
 
 
Magnesium 
stearate(mg) 
3 3 3 - - - 3 3 3 
7 
 
 
Methyl 
paraben(mg) 
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
8 
 
 
Propyl 
Paraben(mg) 
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
9 
 
 
Coating 
material 
sunset 
yellow(mg) 
0.005 0.005 0.005 0.005 0.005 0.005 0.005 0.005 0.005 
 
 
 
 
Total % 
amount 
100 100 100 100 100 100 100 100 100 
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6.4 Formulation development comparative data of various formulations Amlodipine IP     
5mg film coated tablets. 
 
F1 
           Table no: 17 Formula for Amlodipine( F1)IP 5mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
45mg 
 
3 
 
Sodium starch glycolate 
 
 
- 
 
4 
 
Lactose 
 
 
39.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
3mg 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
.005mg 
 
 
 
Total % amount 
 
 
100mg 
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F2 
           Table no: 18 Formula for Amlodipine( F2)IP 5mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
50mg 
 
3 
 
Sodium starch glycolate 
 
 
_ 
 
4 
 
Lactose 
 
 
34.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
3mg 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
0.005mg 
 
 
 
Total % amount 
 
 
100mg 
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F3 
              Table no: 19 Formula for Amlodipine( F3) IP 5mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
55mg 
 
3 
 
Sodium starch glycolate 
 
 
- 
 
4 
 
Lactose 
 
 
29.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
3mg 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
0.005 
 
 
 
Total % amount 
 
 
100mg 
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F4 
             Table no: 20 Formula for Amlodipine (F4) IP 5 mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
45mg 
 
3 
 
Sodium starch glycolate 
 
 
1mg 
 
4 
 
Lactose 
 
 
41.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
- 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
0.005mg 
 
 
 
Total % amount 
 
 
100mg 
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F5 
          Table no: 21 Formula for Amlodipine( F5) IP 5mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
50mg 
 
3 
 
Sodium starch glycolate 
 
 
2mg 
 
4 
 
Lactose 
 
 
35.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
- 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
0.005mg 
 
 
 
Total % amount 
 
 
100mg 
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F6 
              Table no: 22 Formula for Amlodipine (F6) IP 5mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
55mg 
 
3 
 
Sodium starch glycolate 
 
 
3mg 
 
4 
 
Lactose 
 
 
29.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
- 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
0.005mg 
 
 
 
Total % amount 
 
 
100mg 
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F7 
           Table no: 23 Formula for Amlodipine( F7) IP 5 mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
45mg 
 
3 
 
Sodium starch glycolate 
 
 
1mg 
 
4 
 
Lactose 
 
 
38.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
3mg 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
0.005mg 
 
 
 
Total % amount 
 
 
100mg 
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F8 
           Table no: 24 Formula for Amlodipine( F8) IP 5mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
50mg 
 
3 
 
Sodium starch glycolate 
 
 
2mg 
 
4 
 
Lactose 
 
 
32.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
3mg 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
0.005mg 
 
 
 
Total % amount 
 
 
100mg 
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F9 
           Table no: 25 Formula for Amlodipine (F9) IP 5 mg film coated tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
S.NO 
 
INGREDIENTS 
 
 
QUANTITY 
 
1 
 
Amlodipine 
 
 
7mg 
 
2 
 
Starch 
 
 
55mg 
 
3 
 
Sodium starch glycolate 
 
 
3mg 
 
4 
 
Lactose 
 
 
26.4mg 
 
5 
 
Talc 
 
 
5mg 
 
6 
 
Magnesium stearate 
 
 
3mg 
 
7 
 
Methyl paraben 
 
 
0.5mg 
 
8 
 
Propyl paraben 
 
 
0.1mg 
 
9 
 
Coating material sunset yellow 
 
 
0.005mg 
 
 
 
Total % amount 
 
 
100mg 
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6.6 COMPRESION OF TABLETS 
6.6.1 Compression parameters:-  
 The compression is done by using CADMACH 45 station                                                
compression machine specially designed for the compression of tablets having two different 
hoppers for the flow of granules. Two punches are setting in the compression machine for the 
compression of the tablets.  The pressure adjustment devices are used to adjust the pressure in 
the machine. It helps to adjust the weight of the tablet. The granules are passed through the 
two hoppers, and are filled in the die cavity and the final compression takes place with 
desired weight and the hardness being set. Due to the pressure on the upper and the lower 
punch the granules are compressed to get the tablet. 
Weight and the content uniformity of tablet are tested. 
 
Punch specification:- 
Upper punch: 6mm plain round with biweled edges and kg embossed upper punch 
Lower punch: 6mm plain round with biweled edges lower punch 
 
Temperature and relative humidity record 
Temperature: 25-260C 
Relative Humidity: 45-55% 
 
6.6.2Compression parameter 
Description of  tablet :Orange colored round tablet 
Weight of 20tablets : 2.2767g 
Hardness                  : 4.4kg/cm2 
Friability                  : 0.0525% 
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Thickness                 : 3.4mm 
Disintegration time  : 15 minutes 
Individual tablet weight variation: 108mg-119mg 
 
Figure No. 4 Compression process 
6.7 COATING PROCEDURE 
 Coating is done by using the Glatt tablet hi coater with an 
optimized parameter for uniform coating of the tablets without any rough service on the tablet 
and uniformity in the coating achieved by stirring the coating solution continuously during 
coating and the percentage of coating is properly checked by taking the average initial weight 
of 50 tablets before coating and after coating. 
6.7.1 Coating parameters:- 
Inlet temperature: 52-550C 
Exhaust temperature: 38-420C 
Atomization pressure: 3 kg/cm2 
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Pan rpm: 4 rpm 
Gun bed distance: 20-30 cm 
Spray rate: 60 ml/min/3guns 
Peristal pump rpm: 8-12 rpm 
6.8 POST COMPRESSION PARAMETERS 50,51 
 The quantitative evaluation and assessment of a 
tablets,chemical, physical and bioavailability properties are important in the design of tablets 
and to monitor product quality. These properties are important since chemical breakdown or 
interaction between tablet components may alter the physical tablet properties, and greatly 
affect the bioavailability of the tablet system. There are various standards that have been set 
in the various pharmacopoeias regarding the quality of pharmaceutical tablets. This includes 
the diameter, size, shape, thickness, weight, hardness, disintegration and dissolution 
characters. The diameter and the shape depend on the die and punches selected for the 
compression of tablets. The remaining specifications assure that tablets do not vary from one 
production lot to another. The following standards or quality control tests should be carried 
out on compressed tablets. 
 
1. General appearance 
                               The general appearance of tablets, visual identity and overall 
‘elegance’ is essential for consumer acceptance, control of lot-to-lot uniformity and general 
tablet uniformity and for monitoring the production process. The control of general 
appearance involves measurement of attributes such as a tablet’s size, shape, color, presence 
or absence of odour, taste, surface textures, physical flaws and consistency. 
 
2. Size and Shape 
                                             The type of tooling determines the shape and the dimensions of 
compressed tablets during the compression process. At a constant compressive load, tablets 
thickness varies with the changes in die fill, particles size distribution and packing of the 
powder mix being compressed and with tablet weight, while with a constant die fill, thickness 
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varies with variation in compressive load. Tablet thickness is consistent from batch to batch 
or within a batch only if the tablet granulation or powder blend is adequately consistent in 
particle size and particle size distribution, if the punch tooling is of consistent length, and if 
the tablet press is clean and good working condition. 
3. Thickness                                             
                                                  The thickness of individual tablet may be measured with a 
micrometer, which permits accurate measurements and provides information of the variation 
between the tablets. Tablet thickness should be control within a ±5% variation of a standard 
value. Any variations within a particular lot of tablets or between manufactures lots should 
not be apparent to the unaided eye for consumer acceptance of the products. In addition 
thickness must be controlled to facilitate packaging. The physical diamension of tablet along 
with the density of the material in the tablet formulation and their proportions, determine the 
weight of the tablet. The size and the shape of the tablet can also influence the choice of the 
tablet machine to use, the best particle size for granulation, production lot size that can be 
made, the best type of tablet processing that can be use, packaging operations and the cost of 
production.  
                       Six tablets from were randomly selected  from each batch and their thickness 
was measured by using Vernier callipers.The average thickness with standard deviation of the 
tablets from each batch were measured. 
4. Weight variation52,53 
                                             This test is also known as uniformity of weight. This does not 
apply to layer or enteric coated tablet. Weight of individual 20 tablets was noted and their 
mean weight was calculated, and the percentage deviation was calculated by using the 
formula. 
 Percentage deviation = X-X1 × 100 
                                                                   X 
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Where, 
X = actual weight of the tablet 
X1= average weight of the tablet 
Table No. 26 weight variation specification 
 
 
 
 
 
5. Content uniformity 
 The content uniformity test is used to ensure that every tablet 
contain the amount of drug substance intended with little variation among tablet within a 
batch due to increased awareness of physiological availability. The content uniformity test 
has been included in the monograph of all coated and uncoated tablets and all capsules 
intended for oral administration where the ranges of size of the dosage form available include 
50mg or smaller sizes. Tablet monograph with a content uniformity requirements do not have 
weight variation requirements.  
6. Friability 
 Friction and shock are the forces most often cause tablets to 
chip, cap or break. The friability test is closely related to tablet hardness and is designed to 
evaluate the abilility of the tablet to withstand abrasion in packaging, handling and shipping. 
It is usually measured by use of Roche fribilator. A number of tablets are weigh and placed in 
the apparatus . They are exposed to rolling and repeated shocks as they fall 6 inches in each 
turn within the apparatus. After 4 minute of this treatment of 100 revolutions the tablets are 
weighing and the weight compared with the initial weight. The loss due to abrasion is a 
measure of the tablet friability. The values expressed as percentage. A maximum weight loss 
of not more than 1% of the tablet being tested during the friability test is consider generally 
acceptable and any broken or smashed tablet are not picked up. Normally, when capping 
IP/BP LIMIT USP 
80mg or less 10% 130mg or less 
More than 80mg or less 
than 250mg 
7.5% 130mg to 324mg 
250mg or more 5% More than 324mg 
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occurs friability values are not calculated. A thick tablet may have fewer tendencies to cap 
whereas thin tablets of large diameter often show expensive capping, thus indicate in that 
tablets with greater thickness have reduced internal stress.   
 
                                  Friability index = initial weight – final weight 
                                        Initial weight 
 
7. Hardness 
                                      The resistance of tablet to capping, abrasion or breakage under 
conditions of storage, transportation and handling before usage depends on its hardness it is 
now designated as either the Monsanto or Pfizer hardness tester .The instrument measure the 
force required to break the tablets when the force generated by a coil spring is applied 
diametrically to the tablet. 
                                                Hardness which is now more appropriately called crushing 
strength determinations are made during tablet production and are used to determine the need 
for pressure adjustment on tablet machine. If the tablet is too hard, it may not disintegrate in 
the required period of time to meet the dissolution specification; if it is too soft, it may not be 
able to withstand the handling during subsequent processing. Such as coating or packaging 
and shipping operation. The force required to break the tablet is measured in kilograms and 
crushing strength of 4kg/cm2 usually consider to the minimum for satisfactory tablets. Oral 
tablet normally have the hardness 4- 10kg/cm2;However,hypodermic and chewable tablet are 
usually much softer(3 kg/cm2) and some sustained release tablet are much harder(10-
20kg/cm2).Tablet hardness associated with other tablet properties such as densities and 
porosity. Hardness generally increases with normal storage of tablet and depends on the 
shape, chemical properties, binding agents and pressure applied during compression. 
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8. Dissolution. 
 Dissolution is the process by which a solid solute enters a 
solution. In the pharmaceutical industry it may be defined as the amount of drug substance 
that goes in to solution per unit time under standardized conditions of liquid/solid interphase, 
temperature and solvent composition. 
                                             Dissolution behavior of drug has a significant effect on 
pharmacological activity in fact a direct relationship between in vitro dissolution rate of many 
drugs and their solid dosage forms may or may not disintegrate when they interact with 
gastro intestinal fluid following oral administration depending on their design.Dissolution 
kinetics is important in determining the bioavailability of a drug .A variety of designs of 
apparatus for dissolution testing have been proposed and tested, varying of simple beaker 
with stirrer to complex systems. The choice of apparatus to be used depends largely on the 
physiochemical properties of the dosage forms. 
The two types of methods are employed for performing the in vitro dissolution studies 
1. Basket type  
2. Paddle type 
Basket type 
                                      Basket method is used for evaluating the formulations that tend to 
float by carrying out the dissolution study. flotting is due to swelling of the formulation by 
taking some amount of dissolution medium. So in this method the formulation is entrapped 
inside the basket that will not allow the formulation to float even if it swells and becomes 
lighter than the dissolution medium. 
Paddle type 
                                      Paddle method can be used for floating formulations and those 
formulations that don’t float even after swelling. The dissolution apparatus consists of a 
cylindrical vessel made of glass or inert transparent material. The volume of the vessel 
generally used was 900ml.In the vessel dissolution media was taken and the formulation to be 
evaluated had to be placed in it. A shaft is present which is connected at one end to a motor 
and the other end to a basket or paddle according to the method employed. 
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                                          For basket method unless otherwise specified 40 mesh size for the 
basket was used. The rpm of the shaft was 100 rpm for basket method and 50 rpm for paddle 
method .In regular intervals of time samples were withdrawn from the vessel and analyzed 
for the drug release up to each interval by UV visible spectrophotometer. After withdrawing 
the sample it is replaced with same amount of dissolution medium to maintain sink 
conditions. 
8.1 Dissolution for Amlodipine54 
    Medium    :  900ml  0.01M Hydrochloric acid 
    RPM         :  75 rpm 45 Minutes 
    Time         : 5, 10,15,30,45Minutes 
    Apparatus:   paddle 
    Temparature:  370c ± 0.50C 
Preparation of 0.01M Hydrochloric acid dissolution medium 
              5.1 ml Hydrochloric acid in 6 lit water and stirr well to produce 0.01M Hydrochloric 
acid 
Procedure for dissolution 
 Place the tablet in 6 bowls containing 900ml 0.01M Hydrochloric acid  media 
that has been equillibriated to 370C±0.5.Take care to exclude the air bubble of the surface of 
the tablet.Withdraw the suitable  volume of the medium and filter.Measure the absorbance of 
the filtered solution,  at a maximum  about 239 nm.Calculate the content of C20H25ClN2O5 in 
the medium from the absorbance obtained from a solution of  known concentration of 
Amlodipine besilate RS in the same medium.Not less than 70% of the stated amount of 
C20H25ClN2O5. 
    Calculation:                       Emax of standard × 100 
                                           
                                                  Emax of   test 
 
Methodology 
 
R.V.S College of Pharmaceutical Sciences Page 59 
 
9. DRUG CONTENT 
Chromatographic conditions 
 Coloumn:A stainless steel column 15cm×3.9mm. packed with octadecylsilane bonded          
to porous silica 
          Flow rate: 1 ml per minute 
         Wave length : 237 nm 
         Injection volume: 10µl 
         Run time: 12.30 minutes 
Mobile phase:- 
                         A mixture of 15 volume of acetonitrile,35 volume of methanol and 50 volume 
of a solution prepared by dissolving 7.0 ml of triethylamine in 1000ml of water,adjusted to pH 
3.0 with phosphoric acid. 
Test solution (A):-Weigh and powder 20 tablets.Weigh a quantity of  the powder containing 
50 mg of amlodipine,dissolve in the mobile phase,dilute to 50.0ml with the mobile phase and 
centrifuge. 
Test solution(B):-Dilute 5 ml of test solution A to 100.0 ml with the mobile phase. 
Reference solution(A):-A solution of Amlodipine besilate RS containing 0.005 prcent w/v of 
amlodipine in the mobile phase. 
Reference solution (B):-Dilute 5ml of test solution (A) to 100.0ml with mobile phase.Dilute 
5.0 mlof this solution to 50.0 ml with mobile phase. 
Reference solution(C):-Dissolve 5mg of Amlodipine besilate RS in 5ml of strong hydrogen 
peroxide solution.Heat at 700C for 45 minutes and centrifuge. 
Procedure:-Inject 10µl mobile phase ,test solution,reference solution in to chromatograph 
.Record the chromatograms ,and measure the response for major peaks. 
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Calculate % release of Amlodipine using the below equation 
Calculation:- 
 % of Amlodipine 
                                                                      
 TA SW                     SP 
  ×      ×     × 0.7213   ×   Average weight 
                     SA                    TW                   100 
Where, 
    TA= Peak area due to Amlodipine in sample preparation 
    SA= Peak area due to Amlodipine in standard preparation 
    SW= Weight of standard 
    TW= Weight of test 
    SP= Purity of standard 
10. Disintegration Time55,56 
 Randomly selected six tablets from each batch and disintegration  performed 
in disintegration apparatus(Veego,Mumbai) at 37±0.50C. To test for disintegration time, one 
tablet is placed in each tube, and the basket rack is positioned in a one liter beaker of water, 
simulated gastric fluid or simulated intestinal fluid at body temperature such that the tablet 
remain 2.5 cm below the surface of the liquid on their upward movement and descend not 
closer than 2.5 cm from the bottom of beaker. A standard motor device is use to move the 
basket assembly containing the tablet up and down through a distance of 5-6 cm at a 
frequency of 28-32 cycles per minute. To be in compliance with  standards the tablets must 
disintegrate and all the particles must pass through 10 mesh sieve in the time specified. 
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TableNo.27specifications for disintegration time for tablets 
Uncoated tablets NMT15 min in water with disc 370c±20c 
Coated tablets NMT 30 min in water with disc for film 
coated tablets and NMT 60 min for other 
than film coated tablets. 
Enteric coated Intact for 1 hr in 0.01N HCL&disintegrate 
within 2 hr in Mixed phosphate buffer . 
Dispersible/Soluble Within 3 min in water at 250c±10c 
Orodispersible Within 1 min 
Effervescent 5min in 250 ml water at 20-300c 
Buccal and sublingual Not applicable but dissolve within 15-30 min 
 
B) DRUG EXCIPIENT COMPATIBILITY STUDIES 
                            The compatibility of drug and formulation components are important 
perquisite before formulation.It is therefore necessary to confirm that the drug does not react 
with the polymers and excipients.under experimental conditions and affect the shelf life of 
product or any other unwanted effects on the formulations. 
Procedure: 
                    Drug mixed with excipients in different ratio. These mixtures were kept in a 5ml 
glass white colored vials and packed properly. These vials are exposed to room temperature 
and  250C/60%RH& 400C/75%RH.2-3 gm of blend was prepared which was filled in 3 vials. 
Observation for physical appearance were made at zero weeks,1 month, the samples were 
withdrawn for analysis of appearance,moisture content,assay& related substance. 
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 7.   RESULTS AND DISCUSSION 
7.1) PHYSIOCHEMICAL PARAMETERS 
1.DESCRIPTION  
Table no:28 
SL 
NO 
 
DESCRIPTION AMLODIPINE 
 
 
RESULTS 
1 
 
COLOUR White crystalline powder 
2 ODOUR 
 
Odourless 
3 TASTE 
 
Tasteless 
 
2. SOLUBILITY 
Table no:29 
 
 
RAW 
MATERIAL(API) 
 
 
RESULTS 
 
 
 
 
 
 
AMLODIPINE 
 
 
 
 
 
 
 
 
Water:- Slightly soluble 
 
Methanol:- Freely soluble 
 
Ethanol:- Sparingly soluble 
 
2-Propanol:-Slightly soluble 
 
3. pH  ANALYSIS 
Table No:30 
 
 
RAW 
MATERIAL(API) 
 
RESULT 
 
AMLODIPINE 
 
1-6 at 370C 
Results and discussion 
 
R.V.S College of Pharmaceutical Sciences Page 63 
 
 
4. MELTING POINT 
Table no: 31   Melting point            
RAW MATERIAL(API) 
 
MELTING POINT 
 
AMLODIPINE 
 
 
178-1790C 
 
5. CHEMICAL NATURE 
 
Table no:32  Amlodipine specification 
S.NO PARAMETERS 
 
 
AMLODIPINE 
1 Molecular formula 
 
 
C20H25ClN2O5 
2 Molecular weight 
 
 
408.879g ̸ mol 
3 IUPAC name 
 
 
3-ethyl 5-methyl  2-[(2-aminoethoxy]-4-(2-
chlorophenyl)-6-methyl-1,4-dihydropyridine-
3,5dicarboxylate 
4 Chemical nature 
 
 
Long acting 1,4 dihydropyridine calcium 
channel blocker,Antianginal,Antihypertensive 
 
6.HYGROSCOPICITY 
 
Table no:33  Interpretation of results based on percent increase in mass 
 
RAW 
MATERIAL(API) 
 
 
RESULT 
 
Amlodipine 
 
Non hygroscopic 
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7. PARTICLE SIZE ANALYSIS (sieve analysis) 
 
Table No:34 sieve analysis 
 
RAW 
MATERIAL(API) 
 
NATURE OF SAMPLE 
 
 
AMLODIPINE 
 
 
 
 
 
Fine powder 
 
8. FLOW PROPERTY MEASUREMENT 
 ANGLE OF REPOSE 
 
Table no:35 Flow property and corresponding Angle of repose 
        
 
 
 
 
 
 DENSITY 
 
 BULK DENSITY 
 
Table no:36 Bulk density  
RAW MATERIAL(API) 
 
BULK DENSITY g/ml 
 
AMLODIPINE 
 
 
0.625 
 
 
RAW 
MATERIAL(API) 
 
ANGLE OF REPOSE 
 
FLOW PROPERTY 
 
AMLODIPINE 
 
 
34.900 
 
Good 
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 TAPPED DENSITY 
 
Table No:37  Tapped density 
 
RAW MATERIAL(API) 
 
TAPPED DENSITY (g/ml) 
 
AMLODIPINE 
 
 
0.714 
 
 
 COMPRESSIBILITY INDEX 
 
Table No:38   Compressibility Index and corresponding flow property 
RAWMATERIAL 
(API) 
 
COMPRESSIBILITY  
INDEX 
FLOW  
PROPERTY 
 
AMLODIPINE 
 
 
12.46 
 
Good 
 
 HAUSNER’S RATIO 
 
Table No:39  Hausner’s ratio 
RAW MATERIAL 
(API) 
HAUSNER’S  
RATIO 
FLOW  
PROPRTY 
 
AMLODIPINE 
 
 
1.1424 
 
Good 
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9. DRUG CONTENT 
 
Table No:40 Drug content 
RAW MATERIALS(API) 
 
ASSAY (%) 
 
AMLODIPINE 
 
 
103.39% 
 
 
7.2 COMPATIBILITY STUDIES 
 
Table No:41  Compatibility studies of Amlodipine with excipients 
Drug Excipients 
 
(Ratio=1:1) 
 
1st  day 
 
1st  week 2nd week 3rd week 
400 C & 
75% 
RH 
400 C&75% 
RH 
40 0C&75% 
RH 
40 0C&75% 
RH 
 
 
 
 
AMLODIPINE 
Starch Nd  
 
 
Nd Nd Nd 
 
Sodium starch 
glycolate 
Nd Nd Nd Nd 
Magnesium 
stearate 
Nd Nd Nd Nd 
Talc 
 
Nd Nd Nd Nd 
Lactose 
 
Nd Nd Nd Nd 
Methyl paraben 
 
Nd Nd Nd Nd 
Propyl paraben 
 
Nd Nd Nd Nd 
 
Where, 
RH= Relative humidity 
Nd= change not detectable 
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FT-IR SPECTRA OF AMLODIPINE 
Figure No:5 FT-IR spectra of pure drug Amlodipine 
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FT-IR SPECTRA OF AMLODIPINE+ SSG 
Figure No:6 FT-IR spectra of Amlodipine+SSG 
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FT-IR SPECTRA OF OPTIMIZED FORMULATION 
Figure No:7 FT-IR spectra of optimized formulation 
 
 
INFERENCE: Spectrum of pure drug Amlodipine compared with spectrum of Amlodipine 
with excipients.The disappearance or shifting of Amlodipine peak in any of the spectra 
studied.There is no interference to the drug and excipients.  
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7.3 RESULTS AND DISCUSSION 
Table No:42 Precompression parameters of Amlodipine granules trials: 
 
Formulations Bulk 
density 
(gm/cm2) 
Tapped 
density 
(gm/cm2) 
C.I (%) Angle of 
repose(0) 
H.R Moisture 
content 
F1 
 
 
0.42 0.54 32.22 420.21’ 1.383 0.0352 
F2 
 
 
0.49 0.50 20.00 380.65’ 1.222 0.0311 
F3 
 
 
0.48 0.55 18.15 360.23’ 1.25 0.0219 
F4 
 
 
0.41 0.51 28.33 470.32’ 1.42 0.0310 
F5 
 
 
0.43 0.52 27.3 480.26’ 1.382 0.030 
F6 
 
 
0.41 0.51 29.61 460.56’ 1.255 0.0217 
F7 
 
 
0.45 0.55 18.18 310.63’ 1.125 0.0219 
F8 
 
 
0.47 0.55 20.0 300.23’ 1.25 0.0214 
F9 
 
 
0.48 0.51 15.69 280.13’ 1.146 0.0216 
 
Inference: Formulations F1  to F3 has  showing  the  significant  flow property,angle of repose 
and Hausner’s ratio because of  the inclusion of magnesium stearate and lactose,and in case 
of F4-F6 has indicating the high Angle of repose due to the poor flow property in the absence 
of magnesium stearate lubricant.F7-F9 shown good flow as indicated by angle of repose and 
Hausner’s ratio because of  increase in concentration of lubricant magnesium 
stearate.(Magnesium stearate filled the cavities of lactose and this selective adhesion 
improves the flowability of the powder) 
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7.4 POST COMPRESSION PARAMETERS OF AMLODIPINE 
TABLETS  
Table No:43  Post compression parameters of Amlodipine tablets 
Formulations Weight 
variations 
(mg) 
Hardness 
(kg/cm2) 
 
 
Thickness 
(mm) 
Disintegration 
Time(min) 
Friability 
    (%) 
 
F1 
 
 
106-113 
 
4.8 
 
3.64 
 
23 
 
0.069 
 
F2 
 
 
110-120 
 
5 
 
3.43 
 
25 
 
0.059 
 
F3 
 
 
101-112 
 
4.6 
 
3.72 
 
24 
 
0.068 
 
F4 
 
 
98-105 
 
4.2 
 
3.84 
 
20 
 
0.059 
 
F5 
 
 
112-120 
 
5.1 
 
3.44 
 
22 
 
0.062 
 
F6 
 
 
114-120 
 
4.7 
 
3.41 
 
21 
 
0.005 
 
F7 
 
 
108-119 
 
4.3 
 
3.39 
 
20 
 
0.056 
 
F8 
 
 
109-121 
 
4.4 
 
3.12 
 
18 
 
0.052 
 
F9 
 
 
115-118 
 
4.1 
 
3.40 
 
15 
 
0.050 
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7.5 DRUG CONTENT  
 Table No:44 Drug Content Values of Amlodipine                    
FORMULATION AMLODIPINE 
F6 93.21 
            F7 97.54 
F8 98.79 
F9 103.39 
 
Calculation of drug content value of Amlodipine in F9 
 
  
Drug content :-Area of sample × weight of standard × Assay of standard×0.7213×110.33 
                           Area of standard     weight of sample      100 
 
Area of sample=3282559 
Area of standard=2388483 
Weight of standard=52.28mg 
Weight of sample= 1102.50mg 
Assay of standard=99.68% 
 
Drug content :               3282559   ×       52.28       ×     99.68  ×   0.7213  ×   110.33 
                2388483         1102.50             100 
               = 103.39 of LC 
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HPLC CHROMATOGRAM OF AMLODIPINE WITH STANDARD 
Figure No:8 HPLC chromatogram of Amlodipine standard 
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Figure No:9 HPLC chromatogram of sample drug Amlodipine 
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7.6 POST COMPRESSION PARAMETERS OF AMLODIPINE INNOVATOR 
Table No.45 Post compression parameters of Amlodipine innovator 
 
SL.NO 
 
PARAMETERS 
 
 
INNOVATOR 
 
(Amlong) 
 
1 
 
Weight variation 
 
109-117mg 
 
 
2 
 
Hardness 
 
3.8Kg/cm2 
 
 
3 
 
Thickness 
 
3.5mm 
 
 
4 
 
Friability 
 
0.059% 
 
 
5 
 
Disintegration time 
 
12min 
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7.7 DRUG RELEASE 
7.7.1. INNOVATOR DRUG RELEASE PROFILE 
Table No:46 Innovator drug release profile 
 
TIME(MIN) 
 
  INNOVATOR 
 (AMLONG) 
 
5 
 
72.4% 
 
10 
 
84.2% 
 
15 
 
93.7% 
 
30 
 
96.8% 
 
45 
 
98.2% 
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7.7.2 DRUG RELEASE VALUE OF AMLODIPINE 
Table No:47 Percentage Drug release value of Amlodipine 
 
FORMULATIONS 
 
 
% Drug release of Amlodipine 
at 45 minutes 
F1  
80.07% 
 
F2  
82.68% 
 
F3  
84.72% 
 
F4  
84.93% 
 
F5 
 
 
 
87.48% 
F6 
 
 
 
89.50% 
F7 
 
 
 
92.37% 
F8 
 
 
 
94.53% 
F9 
 
 
 
96.87% 
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7.7.3 RELEASE PROFILE OF AMLODIPINE IN F6 COMPARED WITH 
INNOVATOR 
Table No:48 comparative release of amlodipine from innovator and F6 
 
 
Figure No: 10 Release profile of Amlodipine in F6 compared with innovator 
 
 
 
 
Inference:The release profile of the Amlodipine from F6 was less than compared to 
innovator at the end of 45 minutes 
 
 
0
20
40
60
80
100
120
0 10 20 30 40
Release of innovator
Release of F6
Time 
 
%Release of innovator % Release from F6 
 
5 
 
72.4 
 
58.29 
 
10 
 
84.2 
 
62.72 
 
15 
 
93.7 
 
69.54 
 
30 
 
96.8 
 
79.23 
 
45 
 
98.2 
 
89.50 
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7.7.4 RELEASE PROFILE OF AMLODIPINE IN F7 COMPARED WITH 
INNOVATOR 
Table No:49 Comparative release of Amlodipine from innovator and F7  
Time(min) 
 
% Release of innovator % Release from F7 
 
5 
 
72.4 
 
62.2 
 
10 
 
84.2 
 
74.6 
 
15 
 
93.7 
 
80.3 
 
30 
 
96.8 
 
85.9 
 
45 
 
98.2 
 
92.37 
 
Figure No. 11 Release profile of Amlodipine in F7 compared with innovator 
 
 
 
 
 
Inference:  The release profile of Amlodipine from F7 was compared to innovator and the 
release rate was less than the innovator at the end of  45 minutes 
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7.7.5 RELEASE PROFILE OF AMLODIPINE IN F8 COMPARED WITH  
 THE INNOVATOR 
Table No:50 Comparative release of Amlodipine from innovator and F8 
Time(min) 
 
% Release of innovator %Release from F8 
 
5 
72.4 68.53 
 
10 
84.2 75.76 
 
15 
93.7 87.47 
 
30 
96.8 92.64 
 
45 
98.2 94.53 
 
 
Figure No.12 Release profile of Amlodipine in F8 compared with the innovator 
 
 
 
 
Inference:The release profile of Amlodipine from F8 was compared with the innovator and 
the release was compatable to that of innovator at the end of 45 minutes 
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7.7.6 RELEASE PROFILE OF AMLODIPINE FROM F9 COMPARED WITH 
INNOVATOR  
Table No:51 Comparative release of Amlodipine from innovator and F9  
Time(min) 
 
%Release of innovator % Release from F9 
 
5 
72.4 70.69 
 
10 
84.2 82.53 
 
15 
93.7 91.59 
 
30 
96.8 94.12 
 
45 
98.2 96.87 
 
Figure No.13 Release profile of Amlodipine from F9 compared with innovator 
 
 
 
Inference:The release profile of Amlodipine from the F9 was compared with the innovator 
and the release was almost equal and compatable with innovator at the end of 45 minutes. 
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7.7.7 COMPARISON OF DISSOLUTION PROFILE OF FORMULATIONS WITH 
INNOVATOR 
Table No: 52 Comparison of dissolution profile of Amlodipine formulations with innovator  
Time 
(min) 
Innovator 
 
% Release 
                       
                           % Drug Release 
F6 F7 F8 F9 
 
5 
 
 
72.4 
 
58.29 
 
62.2 
 
68.53 
 
70.69 
 
10 
 
 
84.2 
 
62.72 
 
74.6 
 
75.76 
 
82.53 
 
15 
 
 
93.7 
 
69.54 
 
80.3 
 
87.47 
 
91.59 
 
30 
 
 
96.8 
 
79.23 
 
85.9 
 
92.34 
 
94.12 
 
45 
 
 
98.2 
 
89.5 
 
92.37 
 
94.53 
 
96.87 
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7.7.8 COMPARITIVE RELEASE PROFILE OF AMLODIPINE IN VARIOUS 
FORMULATIONS WITH INNOVATOR 
Figure No: 14 Comparative release profile of Amlodipine in various formulations with 
innovator 
 
 
 
 
Inference: Comparative release profile of Amlodipine from various formulations showing 
the release from the F9 matching with the innovator 
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7.8 STABILITY STUDY 
7.8.1 STABILITY DATAS FOR OPTIMIZED FORMULATIONS AT 250C&60%RH 
FOR AMLODIPINE IMMEDIATE RELEASE TABLETS 
Table No: 53 stability data for optimized formulations at 250C & 60% RH for Amlodipine 
immediate release tablet IP 5mg 
S.NO PARAMETERS STORAGE CONDITIONS (250 C& 60% RH) 
 
INITIAL  
 
30 DAYS 45 DAYS 
1 
 
Description 
 
 
Orange colored 
,round shaped 
N.D N.D 
2 Weight variation 
 
 
115-118 Within limits Within 
limits 
3 Hardness 
 
 
4.4 4.4 4.2 
4 Thickness 
 
 
3.4 3.4 3.4 
5 Friability 
 
 
0.052 0.054 0.059 
6 Disintegration time 
 
 
15 15 15 
7 Drug release 
 
 
96.8% 96.% 96% 
8 Drug content 
 
 
103.39 102.75 102.62 
9 Moisture content 
 
 
0.0216 0.0219 0.0321 
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7.7.2 STABILITY DATA FOR OPTIMIZED FORMULATIONS AT 400C &75%RH 
FOR AMLODIPINE IMMEDIATE RELEASE TABLETS 
Table No: 54 stability data for optimized formulations at 400C & 75% RH for Amlodipine 
immediate release tablet IP 5mg 
S.NO PARAMETERS STORAGE CONDITIONS (400 C& 75% RH) 
 
INITIAL  
 
30 DAYS 45 DAYS 
1 
 
Description 
 
 
Orange coloured 
,round shaped 
N.D N.D 
2 Weight variation 
 
 
115-118 Within limits Within 
limits 
3 Hardness 
 
 
4.4 4.4 4.2 
4 Thickness 
 
 
3.4 3.4 3.4 
5 Friability 
 
 
0.052 0.055 0.059 
6 Disintegration time 
 
 
15 15 15 
7 Drug release 
 
 
96.8% 96.82% 96.74% 
8 Drug content 
 
 
103.39 103.35 101.95 
9 Moisture content 
 
 
0.0216 0.0219 0.0231 
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Table No:55 Drug release of Amlodipine at 250C & 60% RH  
DRUG                                  % Drug release 
 
Initial 
 
30 days   45 days 
Amlodipine 96.8 
 
96.78 96.75 
 
 
Figure No:15 Drug release of Amlodipine at 250C&60%RH 
 
 
 
Inference:The drug release was not significantly reduced at the end of 30 days and 45 days 
storage at 250C &60%RH indicating stability of the formulation.All parameters are within the 
specified limits at the end of the storage. 
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Table No:56 Drug release of Amlodipine at 400C & 75% RH  
DRUG                                  % Drug release 
 
Initial 
 
30 days   45 days 
Amlodipine 96.86 
 
96.82 96.74 
 
 
Figure No. 16 Drug release of Amlodipine at 400C & 75% RH 
 
 
 
Inference:The drug release was not significantly reduced at the end of 30 days and 45 days 
storage at 400C &75%RH indicating stability of the formulation.All parameters are within the 
specified limits at the end of the storage. 
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8. SUMMARY AND CONCLUSION 
 
        Totally 9 (n=9) formulations were prepared with Amlodipine  granules ,prepared separately 
in a MCG  mixer. 
       Pre compression parameters like Bulk density , Tapped density ,Angle of repose indicate all             
formulation show good flow properties. 
      Tablets are compressed using CADMACH compression machine and tablets are evaluated 
for post compression parameters like Weight variation,Hardness,Friability,Disintegration and 
Dissolution parameters. 
      Formulation F1-F6 does not meet the criteria for hardness and disintegration time due to the 
improper mixing of lubricant,disintegrant and binder with dry mixture. 
     Formulations F7-F9 has shown post compression within specified limits of the innovator.The 
release profile of the formulations F7-F9 was compared with innovator and all the formulations 
has shown a release of 70-95% and formulation F9(Amlodipine=7mg ,Starch=55mg ,Sodium 
starch glycolate=3mg,Magnesium Stearate=3mg,Lactose=26.4mg  ,Talc=5mg  ,Methyl 
paraben=0.5mg  ,Propylparaben= 0.1mg ,Coloring material(sunset yellow)= 0.005mg ) has 
matched the innovator release profile.F9 has 96.87%  Drug release. 
    The compressed tablets packed in blisters and subjected to stability studies at 400C and 75% 
RH samples were analyzed at regular intervals as mentioned in stability protocol,and found that 
no significant changes observed in any of the studied parameters during the study period,thus it 
could be concluded that formulation F9 said to be stable. 
    From the study, it may concluded that the Amlodipine IP 5mg film coated tablets can be 
prepared as immediate release formulations compared to conventional dosage forms. 
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